Integra to develop modified artificial skin:
This article was originally published in Clinica
Integra Life Sciences has received a $250,000 grant from the US National Institutes of Health to develop an RGD-peptide modified version of its INTEGRA artificial skin, a tissue-engineered product used to treat full-thickness burns and other skin injuries. Early pre-clinical trials indicated that the peptide-enhanced product could accelerate angiogenesis and lead to a faster rate of healing, said the Plainsboro, New Jersey-based company. Integra also received a recommendation for a Phase II grant worth $1.5 million, subject to satisfactory completion of the Phase I programme and certain other conditions.